The Prescription Drug Monitoring Act of 2024 requires states that receive federal funding for prescription drug monitoring programs to implement stronger oversight of controlled substance prescriptions. Starting one year after enactment, covered states must require doctors and other prescribers to check their state's prescription drug monitoring program before starting patients on Schedule II, III, or IV controlled substances and every three months thereafter during treatment. The bill also mandates that pharmacies report dispensed controlled substances to the monitoring program in real time or within 24 hours, and requires state agencies to analyze this data for suspicious patterns, publish their findings publicly, and share information with law enforcement and medical licensing boards. States must also use nationally recognized standards to make their prescription data interoperable and shareable across state lines. States that fail to comply with these requirements risk losing federal grant funding from the Harold Rogers Prescription Drug Monitoring Program and other related federal sources.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.